BOUDRY, Switzerland - Wednesday, January 23rd 2013 [ME NewsWire]

Oral Presentation Scheduled for Friday, January 25th at ASCO’s Gastrointestinal Cancers Symposium Annual Meeting

(BUSINESS WIRE)-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that its phase III clinical trial of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

In the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study, ABRAXANE plus gemcitabine demonstrated a 59% increase in one-year survival (35% vs. 22%, p=0.0002) and demonstrated double the rate of survival at two years (9% vs. 4%, p=0.02) as compared to gemcitabine alone.< ... Read more »

"Government and Business Should Assert the Value of Global Connectivity and Collaborative Efforts”

ME Newswire / Business wire

DAVOS, Switzerland - Wednesday, January 23rd 2013

"At a time of continuing economic uncertainty, nine out of 10 global decision-makers now believe greater collaboration between business, government and other sectors is essential if the world’s economy is to recover.”

This was the main finding of a recent study by PSB, as part of research Bank of America is conducting to better understand customers and clients.

The survey of more than 2,000 global decision-makers across business, government and non-governmental organizations (NGOs) reveals an overwhelming demand for increased collaboration, if significant global growth is to return within the next five years.

Governments and business should assert the value of greater connectivity and collaborative working

Many decision-makers feel governments should assert the v ... Read more »